Akeso (09926.HK) announced that the randomized, double-blind, placebo-controlled, international multi-center Phase II clinical study of the new generation of CD47 monoclonal antibody, Lefaleimab (AK117), independently developed by the company, combined with Azacytidine (AZA) treatment for initial diagnosis of high-risk myelodysplastic syndrome (MDS), has recently completed the enrollment of the first patient in the United States.

The company stated that preliminary studies have shown that AK117 combined with azacitidine has good safety and significant efficacy in the treatment of MDS, and is expected to accelerate the approval and listing process of AK117 globally.